LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from NasdaqGlobeNewsWire • 11/13/25
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineGlobeNewsWire • 11/10/25
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase AgreementPRNewsWire • 10/20/25
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025GlobeNewsWire • 09/30/25
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/25
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of ShareholdersPRNewsWire • 08/08/25
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)PRNewsWire • 08/07/25
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to ShareholdersBusiness Wire • 08/04/25
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/28/25
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027GlobeNewsWire • 12/10/24
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/03/24
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong BuyZacks Investment Research • 07/22/24
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceGlobeNewsWire • 06/20/24
LAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/30/24
LAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/21/24
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceGlobeNewsWire • 05/06/24
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsGlobeNewsWire • 03/20/24
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)GlobeNewsWire • 03/05/24